In a phase I/II trial seven patients with mycosis fungoides were treated with a chimeric (murine/human) anti-CD4 monoclonal antibody with successive increasing doses (10, 20, 40 and 80 mg) twice weekly for 3 weeks. All patients showed some clinical response, with one CR and two PR, but these were all short lived (median duration of 2 weeks).64

A subsequent study from the same group showed PR in 7/8 patients given higher doses (50-200 mg), with median freedom from progression of 28 weeks.65

0 0

Post a comment